GeneDx (WGS) to Release Earnings on Tuesday

GeneDx (NASDAQ:WGSGet Free Report) is set to announce its earnings results after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

GeneDx Stock Up 7.2 %

Shares of NASDAQ:WGS opened at $4.18 on Tuesday. The company has a current ratio of 2.51, a quick ratio of 2.38 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average is $3.06 and its 200 day moving average is $3.43. GeneDx has a 12 month low of $1.16 and a 12 month high of $17.91.

Insider Activity at GeneDx

In other news, CEO Katherine Stueland sold 11,734 shares of the stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $2.16, for a total value of $25,345.44. Following the transaction, the chief executive officer now directly owns 52,578 shares of the company’s stock, valued at $113,568.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Katherine Stueland sold 11,734 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $2.16, for a total transaction of $25,345.44. Following the completion of the transaction, the chief executive officer now directly owns 52,578 shares in the company, valued at $113,568.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jason Ryan purchased 56,742 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were bought at an average cost of $1.27 per share, for a total transaction of $72,062.34. Following the completion of the transaction, the chairman now directly owns 56,742 shares in the company, valued at approximately $72,062.34. The disclosure for this purchase can be found here. Insiders sold 16,950 shares of company stock valued at $36,759 in the last three months. 28.10% of the stock is owned by insiders.

Institutional Trading of GeneDx

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of GeneDx during the first quarter worth about $8,220,000. CVI Holdings LLC acquired a new position in GeneDx during the first quarter worth $3,562,000. Vanguard Group Inc. grew its holdings in GeneDx by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 9,306,795 shares of the company’s stock valued at $8,166,000 after buying an additional 44,467 shares in the last quarter. Geode Capital Management LLC acquired a new stake in shares of GeneDx in the 1st quarter worth $3,129,000. Finally, Marshall Wace LLP raised its holdings in shares of GeneDx by 11.4% during the 4th quarter. Marshall Wace LLP now owns 6,291,730 shares of the company’s stock worth $1,636,000 after acquiring an additional 641,444 shares during the period. 58.05% of the stock is owned by hedge funds and other institutional investors.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Featured Stories

Earnings History for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.